AstraZeneca should not be overlooked for long
03/04/24 -"While AstraZeneca witnessed a phenomenal turnaround in the last decade, the share price has been quiet in the last two years as sentiment has been impacted by a range of factors including too-high ..."
Pages
66
Language
English
Published on
03/04/24
You may also be interested by these reports :
27/02/26
The Q4 sales exceeded expectations, though ‘adjusted’ EBITDA was somewhat behind the consensus. The Q4 performance was driven by LatAm, Animal ...
26/02/26
Even though the H2 25 results were ahead of consensus, the 2026 outlook was below the street’s expectations. While Branded posted strong H2 growth, ...
26/02/26
Novonesis stumbled at the finish line — Q4 25 revenue and EBITDA missed consensus by 2.3% and 2.9% respectively, dragged down by weakness in the ...
26/02/26
The H2 25 results exceeded the consensus, and the 2026 guidance (CER) was better than the consensus estimates at AER. The H2 performance was driven ...